30
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Rhabdomyosarcoma (RMS) is divided into two major histological subtypes: alveolar (ARMS) and embryonal (ERMS), with most ARMS expressing one of two oncogenic genes fusing PAX3 or PAX7 with FOXO1 (P3F and P7F, respectively). The Children's Oncology Group (COG) carried out a multi-institutional clinical trial to evaluate the prognostic value of PAX-FOXO1 fusion status.

          Related collections

          Author and article information

          Journal
          Pediatr Blood Cancer
          Pediatric blood & cancer
          Wiley
          1545-5017
          1545-5009
          Sep 2013
          : 60
          : 9
          Affiliations
          [1 ] Children's Medical Center and University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. stephen.skapek@utsouthwestern.edu
          Article
          NIHMS723539
          10.1002/pbc.24532
          4646073
          23526739
          c0f560b3-f7fd-475e-b7bf-9ff9699cc4fe
          Copyright © 2013 Wiley Periodicals, Inc.
          History

          PAX-FOXO1,rhabdomyosarcoma,survival
          PAX-FOXO1, rhabdomyosarcoma, survival

          Comments

          Comment on this article